Xencor Unternehmenskultur

Dr. John R. Desjarlais, Ph.D. has been Chief Scientific Officer and Senior Vice President of Research at Xencor, Inc. since July 15, 2014. Dr. Desjarlais oversees all aspects of discovery and research at Xencor, Inc., including technology development, protein and antibody engineering and generation of drug candidates. Dr. Desjarlais served as a Vice President of Research at Xencor, Inc. from October 2006 to July 15, 2014. He has driven Xencor, Inc.'s technology development and engineering efforts for over 5 years and participated in the business development and intellectual property strategies. Prior to Xencor, Dr. Desjarlais served as an Assistant Professor of Chemistry at Penn State University, where he developed protein engineering methods similar to Xencor's PDA??? technology platform. Dr. Desjarlais studied BS in Physics from the University of Massachusetts and a Ph.D. in Biophysics from Johns Hopkins University. He then conducted postdoctoral research at the University of California, Berkeley.

Mr. John J. Kuch has been Vice President of Finance at Xencor, Inc. since October 2010 and serves as its Secretary. Mr. Kuch served as Senior Director of Finance at Xencor, Inc. since October 2000. Mr. Kuch has primary responsibility for financial reporting, budgeting, cash-flow management, investments and facility issues for Xencor, Inc. He has extensive experience working with emerging companies through the IPO process. Previously, he worked over 15 years in public accounting as a Director at Price Waterhouse. Mr. Kuch is a C.P.A. and received his B.S. and M.S. in Accounting from the University of Illinois.

Dr. Edgardo Baracchini, Jr., also known as Ed, Ph.D., M.B.A., has been the Chief Business Officer of Xencor, Inc. since January 2010. Dr. Baracchini has more than 20 years of experience in structuring and negotiating research and development partnerships, mergers and acquisitions and in-licensing agreements. To date, Dr. Baracchini has negotiated more than 60 business transactions with multinational and Asian pharmaceutical firms, biotechnology companies and leading universities with leading pharmaceutical and biotechnology companies including Merck, Novo Nordisk, Roche, LG Chem, Boehringer Ingleheim, Zeneca, Incyte Genomics, Medichem, Trega, Axys, Inhale Therapeutics and ICOS. He served as a Senior Vice President of Business Development at Metabasis Therapeutics Inc. from April 2005 to October 23, 2009 and Head of Corporate Development from May 2002 to October 23, 2009. He served as Vice President of Business Development at Metabasis Therapeutics from May 2002 to April 2005. Dr. Baracchini served as the Vice President of Business Development at Elitra Pharmaceuticals since August 1999. From 1997 to 1999, he served as the Director of Business Development at Agouron Pharmaceuticals and as Assistant Director of Business Development at Isis Pharmaceuticals from 1992 to 1996. He also served as Director of Business Development and Strategic Planning at Alanex Corporation from 1996 to 1997. He has been Director of INmuneBio Inc. since October 16, 2017. Dr. Baracchini holds a Ph.D. in Molecular and Cell Biology from the University of Texas at Dallas, an M.B.A. from the University of California, Irvine and a B.S. degree in Microbiology from the University of Notre Dame and Postdoctoral research from Scripps Research Institute.

Dr. Paul A. Foster M.D., F.A.H.A. has been the Chief Medical Officer of Xencor, Inc. since January 2010 and has been its Senior Vice President since December 2015. Dr. Foster served as an Acting Chief Medical Officer at Vaccinex, Inc. Dr. Foster served as the Chief Medical Officer for Cardium Therapeutics and prior to joining Xencor provided Medical/Clinical consulting services as Senior Vice President of Development and Chief Medical Officer of Development and Strategic Consulting Associates, LLC From June 2008 to May 2009. Dr. Foster assumes study oversight responsibilities for both Cardium's and the Tissue Repair Company's clinical programs. He has many years of experience in clinical development for growing biotech companies and also has experience in the medical device arena. Previously, he served as the Chief Medical Officer of Reata Pharmaceuticals Inc., since April 2007 and also served as its Vice President of Clinical and Regulatory Affairs. Previously, Dr. Foster served as Vice President of Global Medical Affairs for Oceanside, California based Biogen IDEC Pharmaceuticals Corp. He has held senior leadership positions in both large and small biopharmaceutical companies including Abbott Laboratories, Alpha Therapeutics, Cardium Therapeutics and Dade Behring. While at Biogen-Idec, Dr. Foster was involved in the management of medical and clinical affair related to several flagship products, including Avonex???, Tysabri???, Zevalin???, and Amevive???. He served as a Director of Abbot Laboratories and Dade Behring. He is Board Certified in Internal Medicine and Hematology. Dr. Foster holds his B.S. degree in Chemistry from the University of Michigan and received an M.D. degree and Medical training at Duke University.

Jade Brown serves as the VP BD for Xencor. Jade started at Xencor in December of . Jade is based in the Greater Los Angeles Area.

Wayne Saville serves as the VP, Clinical Development Oncology for Xencor. Wayne started at Xencor in April of 2015. Wayne is based in the Greater San Diego Area.

John Desjarlais serves as the Chief Scientific Officer for Xencor. John started at Xencor in July of 2014. John is based in the Greater Los Angeles Area.

Jeff Bloss serves as the Chief Medical Officer for Xencor. Jeff started at Xencor in December of . Jeff is based in the Greater Los Angeles Area.